title: Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis.
abstract: The disposition of naltrexone (NLT) (REVIA), an opioid antagonist intended for patients with impaired renal function and with severe intractable itching refractory to regular antipruritic therapy, was characterized. Hemodialysis effects on both efficacy and elimination of NLT also were assessed. We developed a simple, sensitive and selective reverse-phase high-performance liquid chromatographic (HPLC) method for measuring NLT plasma concentration in hemodialysis patients treated to relieve pruritus. NLT and the internal standard, naloxone (NLX) were extracted from plasma using a solid-phase extraction method with sep-pack C18 cartridge. The method was employed to determine both naltrexone pharmacokinetics and dialysability parameters during 4-h in dialyzed patients with chronic renal impairment. Thus, seven patients (2 men, 5 women) with end-stage renal disease and pruritus on regular hemodialysis were included. They received one tablet of NLT (Revia, 50 mg) orally prior dialysis session. The Cmax at the inlet and at the outlet the dialyzer were higher (255+/-117 ng/mL and 206+/-137 ng/ml respectively) in comparison with healthy subjects (9 - 44 ng/mL). The decrease hepatic first-pass metabolism of NLT consecutive to end-stage renal disease and the renal impairment could explain the increased levels of the drug in plasma. Tmax before and after dialysis plates remain unchanged as healthy subjects (approximately 1h). With regard to dialysability, a high dialyzer extraction ratio averating 30 % was found with a low dialysis clearance of 58.70+/-17 mL/min. The amount removed by dialysis is only 1.27 mg. We concluded that hemodialysis has little effect on NLT blood levels, and consequently on drug pharmacokinetics, when the drug is delivered to dialyzed patients following oral route. Thus, dosage adjustement is not required in the presence of advanced dialysis-dependant renal failure. In patients with end-stage renal disease, hemodialysis does not result in clinically significant alterations in the disposition of NLT. Post-dialysis supplementation is not required. These data suggest that there is no pharmacokinetic basis for modification of the initial dosage, but in view of NLT plasma concentration levels in the patients, a clinician could determine whether dosage adjustment are necessary and, if so, make the required calculations accurately.
authors.affiliation: Pharmacology, Pharmacokinetic and Clinical Pharmacy Department, Faculty of Pharmaceutical and Biological Sciences, France.
authors.forename: Nicolas K
authors.initials: NK
authors.lastname: Kambia
authors.forename: Thierry
authors.initials: T
authors.lastname: Dine
authors.forename: Pascal
authors.initials: P
authors.lastname: Odou
authors.forename: Salmane
authors.initials: S
authors.lastname: Bah
authors.forename: Raymond
authors.initials: R
authors.lastname: Azar
authors.forename: Bernard
authors.initials: B
authors.lastname: Gressier
authors.forename: Thérèse
authors.initials: T
authors.lastname: Dupin-Spriet
authors.forename: Michel
authors.initials: M
authors.lastname: Luyckx
authors.forename: Claude
authors.initials: C
authors.lastname: Brunet
mesh_terms: D000982:Antipruritics / Q000378:metabolism* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy; D008297:Male; D009271:Naltrexone / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D000982:Antipruritics; D009271:Naltrexone
references.citation: Lancet. 1996 Dec 7;348(9041):1552-4
references.pmid: 8950882
references.citation: Nephrol Dial Transplant. 1996 Dec;11(12 ):2439-43
references.pmid: 9017619
references.citation: Nephron. 1992;61(1):5-9
references.pmid: 1528340
references.citation: J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):431-4
references.pmid: 10459118
references.citation: J Am Acad Dermatol. 1999 Oct;41(4):533-9
references.pmid: 10495371
references.citation: Nephrol Dial Transplant. 1999 Apr;14(4):834-9
references.pmid: 10328453
references.citation: Br J Clin Pharmacol. 1985 Aug;20(2):155-8
references.pmid: 4041333
references.citation: Inflamm Res. 1997 Oct;46(10):404-6
references.pmid: 9372312
references.citation: Addict Biol. 2002 Apr;7(2):219-25
references.pmid: 12006217
references.citation: Biomed Chromatogr. 2000 May;14(3):151-5
references.pmid: 10850617
references.citation: Therapie. 1987 Oct-Dec;42(6):529-40
references.pmid: 3327192
references.citation: N Engl J Med. 1987 Aug 6;317(6):386
references.pmid: 3600734
references.citation: JAMA. 1992 Dec 16;268(23):3359-62
references.pmid: 1333541
references.citation: Clin Pharmacokinet. 1984 Jan-Feb;9(1):42-66
references.pmid: 6362952
references.citation: Am J Gastroenterol. 1996 May;91(5):1022-3
references.pmid: 8633543
references.citation: Anesth Analg. 1990 Oct;71(4):367-70
references.pmid: 2205128
references.citation: Clin Chem. 1981 Feb;27(2):223-7
references.pmid: 7460271
references.citation: N Engl J Med. 1992 Apr 9;326(15):1016-7
references.pmid: 1545837
references.citation: Gastroenterology. 1997 Oct;113(4):1264-9
references.pmid: 9322521
references.citation: Drug Alcohol Depend. 1998 Nov 1;52(3):211-20
references.pmid: 9839147
references.citation: Gastroenterology. 1992 Aug;103(2):630-5
references.pmid: 1634078
references.citation: Nephrol Dial Transplant. 2001 Sep;16(9):1953-4
references.pmid: 11522892